Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Evoke Pharma, Inc. - Common Stock (NQ:EVOK)

5.070 -0.100 (-1.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Evoke Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Wondering what's happening in today's pre-market session?
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Why Evoke Pharma (EVOK) Stock Is Volatile
Evoke Pharma shares were trading lower by 21.4% during Tuesday's session. The company announced a 1-for-12 reverse stock split of its common stock. 
Via Benzinga
Thursday's after hours session: top gainers and losers
The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
These stocks that are showing activity before the opening bell on Thursday.
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
5 Healthcare Stocks On Fire This Week
Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling breakout potential in biotech & pharma. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Evoke Pharma Posts 47 Percent Q2 Growth
Via The Motley Fool
Evoke Pharma Stock Skyrockets On Patent For Nasal Spray That Eases Stomach Delays; Retail Bulls Pile In
The newly allowed patent covers the use of Gimoti in patients with moderate to severe gastroparesis and is expected to extend market exclusivity through 2036. 
Via Stocktwits
Topics Intellectual Property
Crude Oil Moves Higher; RxSight Shares Plunge
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Evoke Pharma (EVOK) Shares Skyrocket On New Patent: What's Going On?
Shares of Evoke Pharma are trading sharply higher Wednesday morning. The specialty pharma company received a U.S. Patent Office Notice of Allowance for a new patent on its lead product, GIMOTI. 
Via Benzinga
Topics Intellectual Property
Dow Jumps 200 Points; US Wholesale Inventories Fall 0.3% In May
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Earnings Scheduled For March 13, 2025
 
Via Benzinga
Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
S&P 500 Moves Higher; Philips Shares Plunge After Q3 Earnings
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Crude Oil Tumbles Over 5%; Autonomix Medical Shares Spike Higher
 
Via Benzinga
Dow Jumps Over 300 Points; ON Semiconductor Earnings Top Views
 
Via Benzinga
Topics Stocks
Evoke Pharma Stock Is Soaring Monday: What's Going On?
Evoke Pharma Inc (NASDAQ:EVOK) shares are trading higher Monday after the company presented GLP-1 data for users with diabetic gastoparesis using GIMOTI showing statistically significant improvements. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
EVOK Stock Earnings: Evoke Pharma Misses EPS, Misses Revenue for Q2 2024
EVOK stock results show that Evoke Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
EVOK Stock Earnings: Evoke Pharma Beats EPS, Misses Revenue for Q1 2024
EVOK stock results show that Evoke Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.